Home / Stocks / OTSKF

OTSKF (Pharmaceuticals) Stock Valuation & Fair Value Fairly valued

OTSKF (Pharmaceuticals) trades at a blended P/E of 15.5, about 25% below its historical normal valuation, with a forward growth estimate of 6.1% and a PEG of 2.54. Analysts' one-year estimates have been hit 18% of the time.

DATA AS OF 2026-09-21
Blended P/E
15.5
Normal P/E
20.8
PEG
2.54
Fwd growth
6.1%
Div yield
1.7%
RSI (14)
35.5
Neutral

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-09-19.

Blended P/E and rating by weekBlended P/E moved from 15.5 to 15.5 between 2026-09-19 and 2026-09-21, against a normal P/E of 20.8, with 0 rating changes over 2 recorded weeks.2026-09-19: P/E 15.5, Fairly valued (recalculated)2026-09-21: P/E 15.5, Fairly valued16.018.020.0Sep 19Sep 20Sep 21Normal P/E 20.8
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-19P/E 15.5-25%Fairly valued
2026-09-21P/E 15.5-25%Fairly valued ← now

Frequently asked questions

Is OTSKF overvalued?

At a blended P/E of 15.5 versus its historical normal P/E of 20.8, OTSKF trades about 25% below its typical valuation, with a PEG of 2.54 on 6.1% forward growth. tickerseer currently rates it fairly valued.

What is OTSKF's fair value and PEG?

OTSKF trades at a blended P/E of 15.5 against a historical normal P/E of 20.8, a PEG of 2.54, and a forward growth estimate of 6.1%.

Has tickerseer's rating of OTSKF changed?

tickerseer's rating has been fairly valued since 2026-09-19.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track OTSKF free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.